Free Trial

Capricor Therapeutics (CAPR) Competitors

Capricor Therapeutics logo
$10.67 -0.19 (-1.75%)
As of 12:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CAPR vs. CALT, ETNB, DVAX, OCUL, INVA, PCRX, AMPH, BGM, AUPH, and WVE

Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL), Innoviva (INVA), Pacira BioSciences (PCRX), Amphastar Pharmaceuticals (AMPH), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical preparations" industry.

Capricor Therapeutics vs.

Capricor Therapeutics (NASDAQ:CAPR) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Capricor Therapeutics currently has a consensus target price of $35.50, indicating a potential upside of 232.71%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, indicating a potential downside of 1.88%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capricor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Capricor Therapeutics had 25 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 25 mentions for Capricor Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Capricor Therapeutics' average media sentiment score of 0.54 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Capricor Therapeutics Positive
Calliditas Therapeutics AB (publ) Neutral

Capricor Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capricor Therapeutics$17.36M28.07-$22.29M-$1.42-7.51
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62

Capricor Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Capricor Therapeutics' net margin of -146.86%. Capricor Therapeutics' return on equity of -112.95% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Capricor Therapeutics-146.86% -112.95% -57.00%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Capricor Therapeutics received 336 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 63.80% of users gave Capricor Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.

CompanyUnderperformOutperform
Capricor TherapeuticsOutperform Votes
363
63.80%
Underperform Votes
206
36.20%
Calliditas Therapeutics AB (publ)Outperform Votes
27
55.10%
Underperform Votes
22
44.90%

Summary

Capricor Therapeutics beats Calliditas Therapeutics AB (publ) on 14 of the 18 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPR vs. The Competition

MetricCapricor TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$487.88M$6.47B$5.31B$8.31B
Dividend YieldN/A2.64%5.20%4.10%
P/E Ratio-10.088.5926.6919.58
Price / Sales28.07257.78393.58120.51
Price / CashN/A65.8538.2534.62
Price / Book14.626.396.744.47
Net Income-$22.29M$143.98M$3.23B$248.32M
7 Day Performance13.03%-0.06%0.01%-1.26%
1 Month Performance-19.00%1.64%8.69%10.52%
1 Year Performance75.78%-0.73%18.36%8.53%

Capricor Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CAPR
Capricor Therapeutics
1.8223 of 5 stars
$10.67
-1.7%
$35.50
+232.7%
+73.8%$487.88M$17.36M-10.08N/ATrending News
Analyst Forecast
Analyst Revision
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
$39.25
-1.9%
N/A$1.19B$1.60B-21.62180
ETNB
89bio
2.7281 of 5 stars
$8.11
+5.3%
$27.25
+236.0%
+8.1%$1.18BN/A-2.7940Positive News
Gap Down
DVAX
Dynavax Technologies
4.1554 of 5 stars
$9.85
+4.7%
$24.00
+143.7%
-17.3%$1.18B$294.62M54.72350High Trading Volume
OCUL
Ocular Therapeutix
4.2171 of 5 stars
$7.39
+4.7%
$16.25
+119.9%
+20.3%$1.18B$59.65M-5.60230
INVA
Innoviva
4.3358 of 5 stars
$18.61
+0.3%
$55.00
+195.5%
+17.0%$1.17B$369.84M26.97100Positive News
PCRX
Pacira BioSciences
1.9813 of 5 stars
$25.09
-0.1%
$26.44
+5.4%
-15.1%$1.16B$700.97M-12.36720Positive News
AMPH
Amphastar Pharmaceuticals
4.1711 of 5 stars
$24.34
+1.0%
$32.33
+32.8%
-44.3%$1.16B$731.97M8.111,620
BGM
Qilian International Holding Group
N/A$11.42
+3.5%
N/AN/A$1.11B$25.10M0.00298Positive News
Gap Up
AUPH
Aurinia Pharmaceuticals
2.4219 of 5 stars
$8.12
+1.5%
$11.50
+41.6%
+49.5%$1.11B$235.13M-54.13300
WVE
Wave Life Sciences
4.3755 of 5 stars
$6.60
+0.2%
$21.17
+220.7%
-5.4%$1.02B$108.30M-5.95240Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:CAPR) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners